Nature Communications (Aug 2021)
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
- Lars Ny,
- Henrik Jespersen,
- Joakim Karlsson,
- Samuel Alsén,
- Stefan Filges,
- Charlotta All-Eriksson,
- Bengt Andersson,
- Ana Carneiro,
- Hildur Helgadottir,
- Max Levin,
- Ingrid Ljuslinder,
- Roger Olofsson Bagge,
- Vasu R. Sah,
- Ulrika Stierner,
- Anders Ståhlberg,
- Gustav Ullenhag,
- Lisa M. Nilsson,
- Jonas A. Nilsson
Affiliations
- Lars Ny
- Sahlgrenska Cancer Center, Department of Oncology, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital
- Henrik Jespersen
- Sahlgrenska Cancer Center, Department of Oncology, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital
- Joakim Karlsson
- Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital
- Samuel Alsén
- Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital
- Stefan Filges
- Department of Laboratory Medicine, Wallenberg Centre for Molecular and Translational Medicine, Department of Clinical Genetics and Genomics, Sahlgrenska Cancer Center, Institute of Biomedicine, University of Gothenburg and Sahlgrenska University Hospital
- Charlotta All-Eriksson
- Department of Oncology, St. Erik Eye Hospital
- Bengt Andersson
- Department of Clinical Immunology and Transfusion Medicine, Sahlgrenska University Hospital
- Ana Carneiro
- Department of Hematology Oncology and Radiation Physics, Skåne University Hospital, and Institute of Clinical Sciences, Lund University
- Hildur Helgadottir
- Department of Oncology, Karolinska University Hospital
- Max Levin
- Sahlgrenska Cancer Center, Department of Oncology, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital
- Ingrid Ljuslinder
- Department of Oncology, Norrlands University Hospital
- Roger Olofsson Bagge
- Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital
- Vasu R. Sah
- Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital
- Ulrika Stierner
- Sahlgrenska Cancer Center, Department of Oncology, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital
- Anders Ståhlberg
- Department of Laboratory Medicine, Wallenberg Centre for Molecular and Translational Medicine, Department of Clinical Genetics and Genomics, Sahlgrenska Cancer Center, Institute of Biomedicine, University of Gothenburg and Sahlgrenska University Hospital
- Gustav Ullenhag
- Department of Oncology, Uppsala University Hospital
- Lisa M. Nilsson
- Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital
- Jonas A. Nilsson
- Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital
- DOI
- https://doi.org/10.1038/s41467-021-25332-w
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 10
Abstract
The authors report the results of the phase II PEMDAC clinical study testing the combination of the HDAC inhibitor entinostat with the anti- PD-1 antibody pembrolizumab in uveal melanoma. Low tumor burden, a wildtype BAP1 gene in the tumor or iris melanoma correlates with response and longer survival.
